PF-04691502 Dihydrate
P2002
Estimated Purity≥98%
Product group Chemicals
Overview
- SupplierLKT Laboratories
- Product NamePF-04691502 Dihydrate
- Delivery Days Customer7
- CertificationResearch Use Only
- Estimated Purity≥98%
- FormatDMSO 14 mg/mL (32.9 mM); Water Insoluble; Ethanol Insoluble
- Scientific DescriptionPI3K and mTOR inhibitor.
- Storage Instruction-20°C
- UNSPSC12352200
References
- Cirone P, Andresen CJ, Eswaraka JR, et al. Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer. Cancer Chemother Pharmacol. 2014 Mar;73(3):525-38. PMID: 24442130. Wong CH, Loong HH, Hui CW, et al. Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma. Invest New Drugs. 2013 Dec;31(6):1399-408. PMID: 23975511. Yuan J, Mehta PP, Yin MJ, et al. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther. 2011 Nov;10(11):2189-99. PMID: 21750219.